Skip to main content
[Preprint]. 2025 Mar 14:2025.03.13.643116. [Version 1] doi: 10.1101/2025.03.13.643116

Figure 4. High AIMP mRNA expression subgroups are more responsive to anti-angiogenic therapies.

Figure 4.

Kaplan-Meier survival analysis on retrospective clinical trials of recurrent GBM (REGOMA and BELOB trials). High expression sub-groups are stratified by median mRNA expressions of AIMP1/2/3. Log-rank p-value<0.05 is considered significant.